innovation

15 cases — ← All topics

Case Title Lower Court Docketed Status Flags Tags Question Presented
24-950 Urvashi Bhagat v. United States Patent and Trademark Office, et al. Federal Circuit 2025-03-05 Denied Response Waived constitutional-standards due-process expert-testimony innovation nutrition-arts patent-law Whether lower courts erred in prejudicing innovation in nutrition arts by failing to uphold constitutional standards for patent advancement and due pr…
24-47 Return Mail, Inc. v. United States Federal Circuit 2024-07-16 Denied 35-usc-101 abstract-idea alice-corporation-v-cls-bank innovation judicial-interpretation patent patent-eligibility patent-law return-mail-inc-v-united-states-postal-service section-101 Whether the claimed invention is ineligible for patent protection under the abstract-idea exception to 35 U.S.C. §101
21-1093 PersonalWeb Technologies LLC v. Google LLC, et al. Federal Circuit 2022-02-07 Denied Response Waived abstract-idea alice-corp-v-cls-bank computer-implemented-invention computer-implemented-inventions federal-circuit innovation patent-eligibility patent-law technical-field How should courts determine whether a patent for a computer-implemented invention is patent-eligible because it 'improve[s] the functioning of the com…
20-1809 VoIP-Pal.com, Inc. v. Apple, Inc., et al. Federal Circuit 2021-06-29 Denied 35-usc-101 innovation innovation-incentives judicial-framework legal-uncertainty patent-act patent-eligibility patent-law patent-system statutory-interpretation subject-matter-eligibility What is the appropriate standard for determining patent-eligibility under 35 U.S.C. §101?
20-1119 Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al. Federal Circuit 2021-02-16 Denied Amici (3)Response RequestedResponse WaivedRelisted (2) 35-usc-103 graham-factors graham-v-john-deere hindsight-bias innovation innovation-protection nonobviousness-indicia objective-indicia obviousness-standard patent patent-law Whether a court must consider objective indicia of nonobviousness together with the other factors bearing on an obviousness challenge before making an…
20-604 InfoBionic, Inc. v. Cardionet, LLC, et al. Federal Circuit 2020-11-05 Denied 35-usc-101 abstract-idea federal-circuit innovation longstanding-human-practice patent-eligibility patent-monopoly statutory-interpretation Whether the Federal Circuit has properly narrowed the scope of the abstract idea exception under 35 U.S.C. § 101
19-1376 Algignis, Inc. v. Federal Energy Regulatory Commission District of Columbia 2020-06-15 Denied Response Waived administrative-law administrative-state agency-jurisdiction catch-22 civil-rights environmental-law innovation innovation-barriers judicial-review private-enterprise regulatory-capture regulatory-risk standing standing-doctrine Do small, relatively unknown groups have standing to try to solve their own local environmental problems that the government has failed to solve?
19-1103 INO Therapeutics LLC, et al. v. Praxair Distribution Inc., et al. Federal Circuit 2020-03-10 Denied Response Waived 35-usc-101 drug-administration due-process eligibility innovation medical-research medical-treatment method-of-treatment patent patent-eligibility patient-outcomes personalized-medicine section-101 selective-treatment Whether a method of treatment that requires doctors to selectively administer a drug to certain patients and not others to enhance patient outcomes is…
19-1062 CJ CheilJedang Corp., et al. v. International Trade Commission, et al. Federal Circuit 2020-02-26 Denied Amici (1) claim-amendment doctrine-of-equivalents festo-corp-v-shoketsu innovation patent-infringement patent-law prosecution-history-estoppel public-notice public-notice-function tangential-relation Whether, to avoid prosecution history estoppel under Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 'the rationale underlying the amendment' mus…
19-832 Apple Inc. v. VirnetX Inc., et al. Federal Circuit 2019-12-31 Denied Amici (3)Response RequestedResponse WaivedRelisted (2) apportionment apportionment-rule federal-circuit innovation license-valuation patent-damages patent-infringement patent-invalidation pending-litigation prior-licenses Whether the Federal Circuit's reliance on prior licenses to ascertain infringement damages, without satisfying apportionment rules, conflicts with thi…
19-584 Nuvo Pharmaceuticals (Ireland) Designated Activity Company, et al. v. Dr. Reddy's Laboratories Inc., et al. Federal Circuit 2019-11-04 Denied Response Waived 35-usc-112 enablement federal-circuit innovation patent patent-law pharmaceutical pharmaceutical-composition prior-art written-description Whether the Federal Circuit erred by holding that, whenever the prior art teaches away from a pharmaceutical composition, the written description of a…
19-521 ChargePoint, Inc. v. SemaConnect, Inc. Federal Circuit 2019-10-22 Denied Amici (2) 35-usc-101 abstract-idea alice-corp-v-cls-bank alice-v-cls-bank diamond-v-diehr innovation judicial-interpretation machine-or-process patent-eligibility patent-law section-101 Whether a patent claim to a new and useful improvement to a machine or process may be patent eligible even when it 'involves' or incorporates an abstr…
19-522 Trading Technologies International, Inc. v. IBG LLC, et al. Federal Circuit 2019-10-22 Denied abstract-idea civil-procedure computer-implemented-invention computer-implemented-inventions federal-circuit innovation patent-act patent-act-1952 patent-eligibility standing Whether computer-implemented inventions that provide useful user functionality but do not improve the basic functions of the computer itself are categ…
19-353 Trading Technologies International, Inc. v. IBG LLC, et al. Federal Circuit 2019-09-18 Denied Amici (2)Response Waived abstract-idea civil-procedure computer-implemented-invention computer-implemented-inventions federal-circuit innovation patent-act patent-act-1952 patent-eligibility standing Whether computer-implemented inventions that provide useful user functionality but do not improve the basic functions of the computer itself are categ…
18-127 Amgen Inc., et al. v. Sanofi, et al. Federal Circuit 2018-07-27 Denied Amici (1)Response RequestedRelisted (2) 35-usc-112 biotechnology enablement federal-circuit innovation patent-law possession statutory-interpretation written-description Whether the standard for determining the adequacy of the 'written description of the invention' should be as the statute says—that the description mus…